JAZZ PHARMACEUTICALS FRANCE
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT06961266
- Locations
- 🇺🇸
Clinical Trial Site, Columbia, South Carolina, United States
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Conditions
- Breast CancerGastric CancerEsophageal CancerGastroesophageal CancerColorectal CancerEndometrial CancerNon-small Cell Lung CancerOvarian CancerUrothelial CarcinomaSalivary Gland Cancer
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06695845
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona, United States
🇺🇸Rocky Mountain Cancer Center, Littleton, Colorado, United States
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- Conditions
- Metastatic HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06435429
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Canada
🇺🇸Arizona Oncology Tucson - Wilmot, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 286
- Registration Number
- NCT06282575
- Locations
- 🇵🇹
Champalimaud Clinical Center, Lisboa, Portugal
🇵🇹Instituto Português de Oncologia Do Porto Francisco Gentil, EPE, Porto, Portugal
🇷🇴Centrul de Oncologie Euroclinic SRL, Iasi, Romania
VYxeoS Liposomal Italian Observational Study iN the Real Practice
- Conditions
- Therapy-Related Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT06143839
- Locations
- 🇮🇹
Azienda ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹Ospedale Papa Giovanni XXIII, Bergamo, Italy
🇮🇹Ospedale di Bolzano, Bolzano, Italy
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
- Conditions
- Maternal ComplicationsPregnancy ComplicationBirth Outcomes, AdversePregnancy
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT06113237
- Locations
- 🇺🇸
United Biosource LLC, Morgantown, West Virginia, United States
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT06108050
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸California Cancer Associates for Research and Excellence, Fresno, California, United States
🇺🇸Duke University Medical Center - Duke Cancer Institute, Durham, North Carolina, United States
A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy
- Conditions
- Idiopathic HypersomniaNarcolepsy
- Interventions
- Drug: JZP258 (XYWAV)
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 207
- Registration Number
- NCT05875974
- Locations
- 🇺🇸
Advanced Respiratory and Sleep Medicine, PLLC, Huntersville, North Carolina, United States
🇺🇸CTI Clinical Research Center, Cincinnati, Ohio, United States
🇺🇸Intrepid Research, Cincinnati, Ohio, United States
A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT05869773
- Locations
- 🇺🇸
Science 37, Culver City, California, United States
🇺🇸M3 Wake Research, Encino, California, United States
🇺🇸TriValley Sleep Center, San Ramon, California, United States
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
- Conditions
- Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT05864846
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸University of Florida Health - Department of Neurology, Gainesville, Florida, United States